Bending The AAV Manufacturing Cost Curve Through Scalable Platform Innovation, Productivity Gains, And Analytical Insight

For AAV programs approaching commercial scale, transient transfection presents a familiar set of constraints: supply chain dependency on GMP plasmids, process variability, and cost of goods that resist meaningful reduction. A stable producer cell line approach offers a different manufacturing model, and the data presented here makes the performance case for the transition.

The platform uses small molecule chemical induction to trigger AAV production within a stable HEK293 clonal cell line, eliminating plasmids, transfection reagents, and helper virus entirely. Demonstrated titers exceed 1 × 10¹² viral genomes/mL at harvest, with top clones showing 10 to 15-fold productivity gains over transient transfection using clinically relevant constructs. Scalability data spans Ambr 15 through 10 L bioreactors across multiple serotypes, and clonal stability holds across more than 30 passages.

The brochure also addresses development timelines, CMC alignment considerations, and flexible deployment options for teams evaluating the platform. Explore the full data and platform details in the brochure.